An observational study in Valve Disease, Heart, sponsored by Medtronic Cardiac Surgery. Recruiting at 26 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Heart Valve Diseases by Medtronic — 3 open to participants now, 3 under way, none of them phase 3. Heart Valve Diseases · Medtronic.
Among the 17 studies in Heart Valve Diseases by Medtronic, this one is the only one that started in 2019, is one of 6 observational ones, and was the 16th registered.
554 studies on the registry are indexed under Heart Valve Diseases; 164 are open to participants now.
Browse Heart Valve Diseases studies →3 of the 17 studies in Heart Valve Diseases by Medtronic are open now, in 12 countries. Recruiting first, the newest first:
Medtronic Cardiovascular · Sites in United States
Ages 18+
Medtronic Cardiovascular · Sites in United States, Canada, Denmark
Ages 18+
By country, each count listing its studies:
Of the 118 Heart Valve Diseases studies recruiting now, 93 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2019.
This study's planned enrollment of 2,700 is above the median of 300 across 226 observational studies indexed under Heart Valve Diseases.
Median enrollment 63 across the 11 interventional studies, 151 across the 6 observational. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Cardiac Surgery, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiac Surgery is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
1 of the studies in Heart Valve Diseases by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03242642Medtronic CardiovascularTranscatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Heart Valve Diseases by Medtronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This registry is being conducted to support ongoing post-market surveillance activities.
Subjects requiring heart valve therapy replacement and/or repair.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Surgical Heart Valve Repair Products · Device: Surgical Heart Valve Replacement Products
Surgical heart valve repair products.
Surgical heart valve replacement products.
Identify unique failure modes
Time frame: 10 years
Identify trends in adverse device effects
Time frame: 10 years
Not enrolling at this site — choose another above.
Started Dec 2019 (actual). Primary completion is estimated for Dec 2039, 240 months after the start.
Of 115 observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 240 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.